Endocrine Abstracts

Objective: Flash glucose monitoring (FGM) allows non-invasive glucose level assessment. Since November 2020 the use of this system is subsidized in patients with type 3c diabetes (DM3c) Our objective was to describe the characteristics of these patients and their glycemic control expressed as times in range.

Methods and patients: Observational longitudinal clinical study between January 2021 and December 2021 in patients with DM3c in which FGM implementation was subsidized

Results: 26 patients included. Mean age: 59.27 ± 12.22 years, with DM diagnosed with a mean age of 51.85 ± 12.19 years. 30.8% women. 76.9% use of pancreatic enzymes in these patients. FGM metrics: A mean use of 91.17 ± 8.57%. 74.83 ± 16.12% time in range, 16.91 ± 11.82% time between 180–250 mg/dl, 5.35 ± 7.50% time above 250 mg/dl, 2.65 ± 2.99% time between 54–70 mg/dl, 0.13 ± 0.34% time below 54 mg/dl. Glycemic CV 31.59 ± 6.61%. 39.1% of patients achieved all clinical targets for FGM metrics.

Conclusion: - The main cause of DM3c in our series was surgical pancreatic resection (38.5% of patients)

- In our series of patients with DM3c and FGM, metabolic control was adequate using the same clinical targets as in DM1. 39.1% of patients achieved all clinical FGM targets.